Management of atopic dermatitis in the inpatient setting
AbstractPurpose of ReviewDespite the significant burden of inpatient hospitalization for AD, there are few reviews of inpatient management of AD. In this review, we address common indications for hospitalization in AD patients, the role of dermatology consultation, treatment considerations, and discharge planning.Recent FindingsThere are significant socioeconomic and racial/ethnic disparities that lead to increased risk of hospitalization and readmission for AD. A significant burden of mental health disorders in patients with AD can result in psychiatric emergencies and hospitalization in AD patients.SummaryThe mainstay of...
Source: Current Dermatology Reports - May 28, 2021 Category: Dermatology Source Type: research
A Scoping Review of Pharmacotherapy, Complementary, and Alternative Medicine (CAM), and Surgical Therapies for Androgenic Alopecia
AbstractPurpose of ReviewAndrogenic alopecia(AGA) is the most common form of non-scarring alopecia, affecting millions of men and women in the United States (U.S.). This review highlights alternative and complementary treatment options for AGA.Recent FindingsThe treatment regimens for AGA have increased in pharmacotherapeutics, surgical, and complementary (CAM) categories. Each of the different treatment approaches can now be utilized by dermatologists to combat patient hair loss.SummaryThe U.S. Food and Drug Administration (FDA) has approved only two agents to treat AGA: prescription-only, oral finasteride and over-the-co...
Source: Current Dermatology Reports - March 29, 2021 Category: Dermatology Source Type: research
Teledermatology in Military Settings
AbstractPurpose of ReviewThis review summarizes the history and usage of teledermatology in the US Military and potential directions in the future.Recent FindingsGiven the remote and austere environment that operational settings present, it is hard to provide specialized medical care for soldiers who are deployed. Telemedicine has been shown to improve health care in the military. It is well documented that non-life-threatening skin disease comprises the majority of specialty care requests in the deployed setting. Thus, teledermatology is a critical resource in military operational medical settings.SummaryTeledermatology c...
Source: Current Dermatology Reports - March 15, 2021 Category: Dermatology Source Type: research
Teledermatology Addressing Disparities in Health Care Access: a Review
AbstractPurpose of ReviewDermatologists have been at the forefront of researching telemedicine to expand access to care. The current COVID-19 pandemic has prompted even greater expansion and implementation of teledermatology. This review discusses the research examining the potential impact of teledermatology addressing disparities in care.Recent FindingsTeledermatology appears to increase access to dermatology given expanded means to deliver care. Specifically, recent studies have found increased access among Medicaid-insured, resource-poor urban and rural, and elderly populations. Teledermatology implementation also faci...
Source: Current Dermatology Reports - March 12, 2021 Category: Dermatology Source Type: research
Advancements in Biologic Therapy for Psoriasis: the IL-23 Inhibitors
AbstractPurpose of ReviewThe purpose of this article is to review clinical trials evaluating the efficacy and safety of IL-23 inhibitors in the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis.Recent FindingsGuselkumab, tildrakizumab, and risankizumab have been approved for the treatment of psoriasis. Mirikizumab is still under investigation in phase 3 studies. IL-23 inhibitors show excellent efficacy and outperform other biologic therapies in multiple head-to-head trials. Network meta-analyses have demonstrated that IL-23 inhibitors have superior long-term efficacy, while IL-17 inhibitors have supe...
Source: Current Dermatology Reports - March 1, 2021 Category: Dermatology Source Type: research
Halobetasol Propionate and Tazarotene Combination Lotion 0.01%/0.045% for Psoriasis
This article reviews in detail the merits and unique nature of this combination lotion and also discusses a new type of strategy for treating psoriasis topically.Recent FindingsThe combination lotion proved much more efficacious than the vehicle. Moreover, when the combination lotion was compared head-to-head with each of the components alone (halobetasol, tazarotene) and vehicle lotion, the combination was clearly more efficacious after 8 weeks. In terms of safety, the combination lotion was well tolerated by the patients. The combination lotion is also unique in that it is the only superpotent topical steroid with long...
Source: Current Dermatology Reports - March 1, 2021 Category: Dermatology Source Type: research
Phototherapy for Psoriasis: New Research and Insights
AbstractPurpose of ReviewThe purpose of the review is to highlight some of the new findings on phototherapy treatment for psoriasis and present clinical pearls for the practitioner.Recent FindingsRecent research has helped to further elucidate the molecular mechanisms of UV light in the treatment of psoriasis. New evidence regarding the combination of phototherapy with biologic agents and phototherapy ’s effect on quality of life is also highlighted.SummaryPhototherapy remains an effective and viable option for patients seeking non-invasive and safe treatment of psoriasis. Further research is still needed to understand t...
Source: Current Dermatology Reports - March 1, 2021 Category: Dermatology Source Type: research
Deucravacitinib for Psoriasis
This article reviews the mechanism and significance of TYK2 inhibition, as well as the current data on the safety and efficacy of deucravacitinib.Recent FindingsPhase II results for deucravacitinib have shown that four out of six treatment groups resulted in statistically significant increases in PASI75 improvement over the placebo group. The most common adverse effects were headache, nasopharyngitis, upper respiratory tract infection, nausea, acne, and diarrhea. Three serious adverse events were noted in the treatment group, and they were gastroenteritis due to rotavirus, accidental eye injury, and dizziness.SummaryDeucra...
Source: Current Dermatology Reports - March 1, 2021 Category: Dermatology Source Type: research
Molecular Methods for Detection of Beta and Gammapapillomaviruses for Non-melanoma Skin Cancer
AbstractPurpose of reviewHuman Papillomaviruses (HPV) have some associations with that of the beta and gamma genera with non melanoma skin cancers (NMSC). The detection of HPV in clinical specimens is molecular-based since the isolation of the virus in in vitro cell lines has not been achieved. In this contest, we provide information about the choices of molecular methods applicable in epidemiological surveys.Recent findingsA limited number of assays have been developed to detect and genotype cutaneous HPVs (associated with NMSC). Consensus PCR followed by hybridization, consensus PCR followed by sequencing, multiplex PCR,...
Source: Current Dermatology Reports - March 1, 2021 Category: Dermatology Source Type: research
Deucravacitinib for Psoriasis
This article reviews the mechanism and significance of TYK2 inhibition, as well as the current data on the safety and efficacy of deucravacitinib.Recent FindingsPhase II results for deucravacitinib have shown that four out of six treatment groups resulted in statistically significant increases in PASI75 improvement over the placebo group. The most common adverse effects were headache, nasopharyngitis, upper respiratory tract infection, nausea, acne, and diarrhea. Three serious adverse events were noted in the treatment group, and they were gastroenteritis due to rotavirus, accidental eye injury, and dizziness.SummaryDeucra...
Source: Current Dermatology Reports - January 7, 2021 Category: Dermatology Source Type: research
Halobetasol Propionate and Tazarotene Combination Lotion 0.01%/0.045% for Psoriasis
This article reviews in detail the merits and unique nature of this combination lotion and also discusses a new type of strategy for treating psoriasis topically.Recent FindingsThe combination lotion proved much more efficacious than the vehicle. Moreover, when the combination lotion was compared head-to-head with each of the components alone (halobetasol, tazarotene) and vehicle lotion, the combination was clearly more efficacious after 8 weeks. In terms of safety, the combination lotion was well tolerated by the patients. The combination lotion is also unique in that it is the only superpotent topical steroid with long...
Source: Current Dermatology Reports - January 6, 2021 Category: Dermatology Source Type: research
Advancements in Biologic Therapy for Psoriasis: the IL-23 Inhibitors
AbstractPurpose of ReviewThe purpose of this article is to review clinical trials evaluating the efficacy and safety of IL-23 inhibitors in the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis.Recent FindingsGuselkumab, tildrakizumab, and risankizumab have been approved for the treatment of psoriasis. Mirikizumab is still under investigation in phase 3 studies. IL-23 inhibitors show excellent efficacy and outperform other biologic therapies in multiple head-to-head trials. Network meta-analyses have demonstrated that IL-23 inhibitors have superior long-term efficacy, while IL-17 inhibitors have supe...
Source: Current Dermatology Reports - January 4, 2021 Category: Dermatology Source Type: research
Phototherapy for Psoriasis: New Research and Insights
AbstractPurpose of ReviewThe purpose of the review is to highlight some of the new findings on phototherapy treatment for psoriasis and present clinical pearls for the practitioner.Recent FindingsRecent research has helped to further elucidate the molecular mechanisms of UV light in the treatment of psoriasis. New evidence regarding the combination of phototherapy with biologic agents and phototherapy ’s effect on quality of life is also highlighted.SummaryPhototherapy remains an effective and viable option for patients seeking non-invasive and safe treatment of psoriasis. Further research is still needed to understand t...
Source: Current Dermatology Reports - January 4, 2021 Category: Dermatology Source Type: research
Correction to: Systemic Photoprotection
The original version of this article did not include the results from articles showing a more favorable side effect profile with a controlled-release subcutaneous implant of afamelanotide. (Source: Current Dermatology Reports)
Source: Current Dermatology Reports - December 1, 2020 Category: Dermatology Source Type: research
